Crescent Biopharma (CBIO) Preferred Stock Liabilities (2024 - 2025)
Crescent Biopharma (CBIO) posted quarterly Preferred Stock Liabilities of $4.0 million for Q1 2025, little changed quarter-over-quarter from $4.0 million in Q4 2024.
Crescent Biopharma (CBIO) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has reported Preferred Stock Liabilities for 2 consecutive years, with $4.0 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Preferred Stock Liabilities changed N/A year-over-year to $4.0 million; the TTM figure through Mar 2025 stood at $4.0 million (changed N/A YoY), while the FY2024 annual figure was $4.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $4.0 million in Q1 2025 per CBIO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $4.0 million in Q3 2024 and bottomed at $4.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |